Diabench POCT Test Card Obtains Ethiopian FDA Registration: One Card Solution for Blood Grouping, HIV, HCV, HBsAg and Syphilis Detection
We are proud to announce that our flagship product, Diabench POCT test card, has officially obtained registration from the Ethiopian Food and Drug Authority. This significant achievement marks an important milestone for our company and highlights our commitment to delivering high-quality in vitro diagnostic solutions to the healthcare market in Ethiopia. The approval confirms that the Diabench POCT test card meets stringent regulatory standards for safety, quality, and performance.
As a professional POCT manufactory, we designed the Diabench POCT test card to provide comprehensive and reliable rapid testing in a single, convenient format. The Diabench POCT test card integrates blood grouping, HIV, HCV, HBsAg, and syphilis detection into one compact card, offering a true all-in-one diagnostic solution. This multi-parameter capability significantly improves workflow efficiency in hospitals, laboratories, blood banks, and clinics.
With the Diabench POCT test card, healthcare providers can determine blood grouping and screen for major infectious diseases quickly and accurately. By combining five critical assays in one Diabench POCT test card, laboratories can reduce testing time, minimize sample handling, and lower overall operational costs. This integrated approach not only enhances productivity but also reduces the risk of cross-contamination and human error.
The Ethiopian FDA registration of the Diabench POCT test card demonstrates our strong technical capabilities and strict quality management system. Through comprehensive evaluation and documentation review, the Diabench POCT test card proved its reliability, sensitivity, and specificity in clinical performance. Achieving this certification reflects our dedication to meeting international standards and supporting global healthcare systems with dependable POCT products.
In many regions of Africa and other developing markets, access to fast and accurate diagnostics remains essential. The Diabench POCT test card addresses this need by delivering rapid results without the requirement for complex laboratory infrastructure. Because the Diabench POCT test card supports rapid decision-making, it is especially valuable in emergency settings, rural clinics, and blood donation centers where timely screening is critical.
Quality is at the core of every Diabench POCT test card we manufacture. Each Diabench POCT test card is produced under strict quality control procedures, from raw material sourcing to final packaging. Before shipment, every Diabench POCT test card undergoes rigorous inspection and validation to ensure stable performance and long shelf life. Our advanced production facilities and experienced R&D team ensure continuous product improvement and innovation.
For distributors and partners, the Diabench POCT test card offers strong market competitiveness thanks to its multi-disease detection capability and regulatory approval. The compact design of the Diabench POCT test card makes transportation and storage convenient, helping partners reduce logistics costs while expanding their diagnostic portfolio. With increasing demand for point-of-care testing solutions, this product provides excellent opportunities for growth.
Looking ahead, we will continue to promote the Diabench POCT test card in global markets and pursue additional international certifications. The Ethiopian FDA registration of the Diabench POCT test card marks only the beginning of our broader expansion strategy. We invite healthcare institutions, distributors, and industry partners to experience how the Diabench POCT test card can transform routine screening and infectious disease detection.
With its multi-disease capability, regulatory approval, and user-friendly format, the Diabench POCT test card stands out as a reliable and efficient diagnostic solution. Choose the Diabench POCT test card for accurate blood grouping and infectious disease screening in one card, and join us in advancing accessible, high-quality healthcare worldwide.
